Navigation Links
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
Date:12/10/2008

done palmitate treatment groups received a 150 mg eq. injection in the deltoid muscle. On day 8 and every 4 weeks for the duration of the trial they received the randomly assigned fixed dose (25, 100 or 150 mg eq.) in the deltoid or gluteal muscle. The primary endpoint of the trial was change in PANSS(c) total score from baseline to endpoint.

The results showed that with the 150 mg eq. initiation dose, patients taking paliperidone palmitate at any of the three doses (25, 100, or 150 mg eq.) had significantly improved symptoms, based on the primary outcome parameter of change in PANSS total scores, compared to patients on placebo (p is less than or equal to 0.034). Symptoms improved with increased dosage, with those taking the 150 mg eq. dose showing the greatest improvement. Overall treatment-emergent adverse events (TEAEs) occurred at similar rates among the paliperidone palmitate (60-63%) and placebo (65%) groups. The number of patients who reported serious TEAEs was higher in the placebo group (14%) than in any of the paliperidone palmitate groups (25 mg eq. 9.4%; 100 mg eq. 13.3%; 150 mg eq. 8.0%). Common TEAEs occurring greater than or equal to 2% more frequently in the total paliperidone palmitate group compared to the placebo group were injection site pain (placebo, 3.7% vs 7.6% with paliperidone palmitate), dizziness (placebo 1.2% vs 2.5% with paliperidone palmitate), sedation (placebo 0.6% vs 2.3% with paliperidone palmitate), pain in extremity (placebo 0% vs 1.6% with paliperidone palmitate) and myalgia (placebo 0% vs 1.0% with paliperidone palmitate). The overall safety profile was similar to previously published studies of paliperidone ER in the treatment of schizophrenia(1,2).

The authors concluded that using a 150 mg eq. deltoid initiation dose followed by subsequent injections every 4 weeks of 25-150 mg eq. of paliperidone palmitate produced statistically significant symptom control as measured by the P
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. SemBioSys begins phase I/II trial of insulin produced in plant seeds
10. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
11. OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability , ... and insect pressures , Syngenta ... opening celebration today at the company’s RTP Innovation Center. ... Lab allows company researchers to simulate any agricultural climate ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to ... Switzerland -based Kenta Biotech to ... antibody (mAb) products, and technologies. This asset portfolio ... treatment of infections by common pathogens including drug ... Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... Frederick, MD (PRWEB) May 17, 2013 ... release of ezColony version 4.1, a versatile refinement ... world-class premier software solution, improves its advanced methodical ... animal facilities with ezColony 4.1. The network-based platform ... to conduct effective research. While continuing to emphasize ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 The ... by Global Cooling, Inc., Athens, OH, USA, won the ... by the International Society for Biological and Environmental Repositories ... award, given to one product annually, recognizes the company’s ... ultra-low temperature freezer. The award was presented to ...
Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2
... Inhibitor (human)] Commercial Launch --EXTON, Pa., Feb. 24 ViroPharma ... results for the fourth quarter and year ended December 31, ... , ... 2008; , Initiated commercial ...
... DiagnosticsSALT LAKE CITY, Feb. 24 Axial Biotech, ... development of molecular diagnostic technologies, announced today that ... management team as the company,s new Vice President ... directly to Kenneth Ward, M.D., Chairman and Chief ...
... 23 Smith & Nephew, Inc.,(NYSE: SNN ... the,introduction of VISIONAIRE Patient Matched instrumentation for use in ... that,uses a patient,s MRI and x-rays to create custom ... of high performance knee implants. , ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 12Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 3
(Date:5/16/2013)... developed at MIT may someday eliminate the need ... monitor their blood-sugar levels and inject themselves with ... glucose levels in the body and respond by ... the function of pancreatic islet cells, which are ... this type of system could ensure that blood-sugar ...
(Date:5/16/2013)... Philadelphia, PA, May 16, 2013 The relationship ... intelligence (IQ) has not been clear. Schizophrenia is ... functional disability. There are clues that reduced IQ ... schizophrenia. For example, reduced cognitive ability may precede ... may be present in healthy relatives of people ...
(Date:5/16/2013)... S.C. , May 16, 2013 ... in combination with a custom thin film transistor ... highest forensic quality roll image in the smallest ... today. Sherlock, an Appendix F Mobile ID FAP ... a 95% reduction in size and weight when ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Genetic risk for schizophrenia is connected to reduced IQ 2
... of 35 headwater basins in the United States and Canada ... rates was less than expected in many locations, suggesting that ... change. The study was just published in a special ... Long-Term Ecological Research (LTER) network of 26 sites around the ...
... Notre Dame,s Eck Institute for Global Health developed a ... drug resistance, an effort that will allow for real-time ... The new discovery is described in a paper appearing ... Science . The team of researchers includes Notre ...
... women will be diagnosed with breast cancer during her ... chance of successful treatment and long-term survival. However, early ... remains cumbersome, costly, and in many cases, cancer can ... based in the Dept. of Biomedical Engineering at McGill ...
Cached Biology News:Impact of warming climate doesn't always translate to streamflow 2Notre Dame researchers using novel method to combat malaria drug resistance 2Notre Dame researchers using novel method to combat malaria drug resistance 3Detecting breast cancer's fingerprint in a droplet of blood 2
... SilverQuest Silver Staining Kit is uniquely ... sensitivity with minimal protein modification for ... spectrometry problems associated with traditional silver ... kit because the reagents used do ...
...
... Insect Medium is formuatled for the ... Sf9 and Sf21 cells. Grace's Insect ... because it does not contain lactalbumin ... with transfection. Grace's Insect Medium, Supplemented ...
Schneider's Drosophila Medium is formulated for the expression of heterologous proteins in Drosophila S2 cells....
Biology Products: